Fujisawa Pharmaceutical Company, Ltd.

Astellas Pharma Gmbh

R-tech Ueno, Ltd.

Mitsuru Ohkubo

Hisashi Takasugi

Toshio Yamanaka

Masayuki Kato

Atsushi Kuno

Masataka Morita

Takayuki Inoue

Kousei Yoshihara

Takashi Tojo

Satoru Kuroda

Fumie Takahashi

Hideko Nakamura

Akira Nagashima

Seiji Yoshimura

Toshiaki Aoki

Yosuke Fujii

Hiroyoshi Sakai

Shunsuke Goto

Jiro Seki

Masatoshi Minagawa

Hidenori Nakajima

Keiichi Koga

Ryoki Orii

Kayoko Harada

Eiki Oikawa

Kaori Nishio

Nobuya Nishio

Kousel Yoshihara

A compound of the formula (I): R&#x2014;NH&#x2014;X&#x2014;Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.

Thiazole derivatives

It is intended to provide a protein participating in the regulation of sugar production, a polynucleotide encoding the same, a method of screening a compound participating in the regulation of sugar production and a drug for treating or preventing diabetes which contains the compound participating in the regulation of sugar production. A polynucleotide encoding a protein specifically binding to a substance WF00144 is found out from rat liver cells and thus a protein participating in the regulation of sugar production and a polynucleotide encoding the same are provided. Moreover, a method and a substance relating to a method of treating and preventing diabetes are found out and thus a method of treating diabetes relating to the regulation of sugar production relating to the method of treating and preventing diabetes is provided.

Polynucleotide encoding a 35 KDA protein thats binds to WF00144

A beta-alanine derivative of the formula (I) wherein R is hydrogen atom or an amino protective group; A is a lower alkylene group or a lower alkenylene group; R is hydrogen atom or an amino group which may be substituted with an acyl group; R is hydrogen atom or an aryl or aralkyl group which may be substituted with one or more of hydroxy and/or lower alkoxy, a moiety represented by the formula (II), which is a bivalent N-containing 6- to 8-membered heterocyclic group, or a pharmaceutically acceptable salt thereof.

Beta-alanine derivatives and their use as receptor anatgonists

N-&lsqb;(R)-1-&lsqb;3-(4-piperidyl)propionyl&rsqb;-3-piperidylcarbonyl&rsqb;-2(S)-acetylamino-&bgr;-alanine trihydrate, compositions thereof, and methods for its use

&bgr;-alanine compounds or a pharmaceutically acceptable salt thereof, which is useful as a glycoprotein IIB/IIIa antagonist, inhibitor of blood platelet aggregation and inhibitor of the binding of fibrinogen to blood platelet; a composition containing the same, a process for the preparation of the compound, and a process for the treatment of diseases caused by thrombus formation, for example, are provided.

N-acylpiperidinylcarbonylaminocarboxylic acids and their use as glycoprotein IIb/IIIa antagonists and fibrinogen-blood platelets binding inhibitors

Beta-alanine derivative and a process for the preparation thereof

Oxadiazole derivatives having acetylcholinesterase-inhibitory and

The invention relates to a compound useful as an anticonvulsant, and for treatment of delayed neuronal death, the compound being a bicyclic amine of the formula: ##STR1## wherein R.sup.1 is lower alkyl,

Bicyclic amine compound and a process for the preparation thereof

Growing community of inventors

Osaka, Japan

Mitsuru Ohkubo